Pharmaceuticals and Tax Outlook

Vaccine development, a presidential election, and IRS activity are among some of the concerns facing organizations within the pharmaceutical industry – and their tax outlook.

The Latest Tax Implications on Pharma special report provides you insight for effective decision-making across one of the most significant catalysts on the path to pandemic recovery.

Explore the following key pharmaceutical concerns:

  • Indonesia’s R&D tax deductions related to vaccine development
  • Considerations for maximizing virtual mediation in a practice likely to continue beyond the pandemic
  • Path to economic recovery and impact of the Trump vs. Biden presidential race
  • Benefits to pharmaceutical companies of government investments in research
  • Strategies multinationals use to lower U.S. tax bills and the relevance of Section 704(c) and Section 721

Download your copy to strengthen your insight and inform your stakeholders.

This site is protected by reCAPTCHA and the Google Privacy Policy, and Terms of Service apply.

By submitting my information, I agree to the privacy policy and to learn more about Bloomberg Industry Group products and services.

Sending...